Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

34
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
34
Factors Affecting Renal Clearance: Renal Impairment01:17

Factors Affecting Renal Clearance: Renal Impairment

30
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
30
Drug Dosage Regimen: Overview01:15

Drug Dosage Regimen: Overview

3.3K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
3.3K
Rational Dosage Regimen: Maintenance Dose and Loading Dose01:24

Rational Dosage Regimen: Maintenance Dose and Loading Dose

3.6K
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
3.6K
Renal Drug Clearance: Overview01:06

Renal Drug Clearance: Overview

66
Renal clearance is a crucial parameter in pharmacokinetics that quantifies the rate at which the kidneys excrete a drug. It represents a constant fraction of the central volume of distribution containing the drug that the kidney eliminates per unit of time.
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...
66
Dosage Regimen: Fixed Dose01:01

Dosage Regimen: Fixed Dose

1.8K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phenotypic Spectrum of HNF4α-Associated Fanconi Renotubular Syndrome.

Kidney international reports·2026
Same author

Scoping Review of Global Kidney Genetics Clinic Models and Outcomes.

Kidney international reports·2026
Same author

Executive summary of the European consensus report on the diagnosis and treatment of monoclonal gammopathy of renal significance.

Clinical kidney journal·2026
Same author

Automated reanalysis of genomic data for rare disease diagnostics at scale.

Nature medicine·2026
Same author

Autosomal Dominant Polycystic Kidney Disease: Genetic Insights, Phenotypic Spectrum, and Advances in Prognosis and Treatment.

Advances in kidney disease and health·2026
Same author

Long-Read Sequencing in CKD Diagnostics: Breaking Genomic Barriers and Expanding Global Inclusion.

Kidney international reports·2026

Related Experiment Video

Updated: May 10, 2025

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
07:13

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform

Published on: April 12, 2021

4.2K

Integrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into

Geeta Sandhu1,2,3, Josephine Adattini2, Evangeline Armstrong Gordon2

  • 1Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.

Eclinicalmedicine
|April 28, 2025
PubMed
Summary

The International Consensus Guideline on Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) provides updated drug-specific recommendations for chemotherapy dosing in patients with impaired kidney function. These guidelines aim to improve cancer treatment safety and efficacy by refining existing protocols.

Keywords:
ChemotherapyDrug dosingHaematologyKidney dysfunctionOncologyPharmacokineticsRenal

More Related Videos

Guided Differentiation of Mature Kidney Podocytes from Human Induced Pluripotent Stem Cells Under Chemically Defined Conditions
08:06

Guided Differentiation of Mature Kidney Podocytes from Human Induced Pluripotent Stem Cells Under Chemically Defined Conditions

Published on: July 2, 2020

4.5K
Direct Drug Delivery to Kidney via the Renal Artery
11:18

Direct Drug Delivery to Kidney via the Renal Artery

Published on: April 17, 2021

7.1K

Related Experiment Videos

Last Updated: May 10, 2025

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
07:13

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform

Published on: April 12, 2021

4.2K
Guided Differentiation of Mature Kidney Podocytes from Human Induced Pluripotent Stem Cells Under Chemically Defined Conditions
08:06

Guided Differentiation of Mature Kidney Podocytes from Human Induced Pluripotent Stem Cells Under Chemically Defined Conditions

Published on: July 2, 2020

4.5K
Direct Drug Delivery to Kidney via the Renal Artery
11:18

Direct Drug Delivery to Kidney via the Renal Artery

Published on: April 17, 2021

7.1K

Area of Science:

  • Oncology
  • Nephrology
  • Pharmacology

Background:

  • Kidney dysfunction significantly impacts anticancer drug efficacy and toxicity.
  • Existing guidelines for chemotherapy dosing in renal impairment vary and may not reflect current evidence.
  • The International Consensus Guideline on Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) was developed to address these limitations.

Purpose of the Study:

  • To provide evidence-based, consensus recommendations for anticancer drug dosing in patients with kidney dysfunction.
  • To compare ADDIKD recommendations with existing guidance for commonly used anticancer agents.
  • To translate complex recommendations into practical clinical guidance.

Main Methods:

  • Development of consensus recommendations based on systematic evidence review and expert clinical experience.
  • Comparative analysis of ADDIKD dosing for methotrexate, cisplatin, carboplatin, and nivolumab against current standards.
  • Distillation of recommendations into actionable practice points for specific agents.

Main Results:

  • ADDIKD Part 2 offers specific dosing recommendations for anticancer drugs in kidney dysfunction.
  • Significant differences were observed between ADDIKD and existing guidance for methotrexate, cisplatin, carboplatin, and nivolumab.
  • Practical guidance was developed for methotrexate and cisplatin dosing.

Conclusions:

  • The ADDIKD guideline represents a significant advancement in managing chemotherapy in renal impairment.
  • Successful adoption requires stakeholder endorsement, clinician advocacy, and integration into clinical workflows and systems.
  • Implementation is crucial for optimizing cancer treatment outcomes in patients with kidney disease.